{"commentary":{"count":90,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":31,"youtube":30,"podcast":29},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04744831\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"DESTINY-CRC02","nct_id":"NCT04744831","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=destiny-crc02-nct04744831. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"DESTINY-CRC02","arms":[{"description":"Participants will be randomized to receive intravenous T-DXd administered at a dose of 5.4 mg/kg every 3 weeks (Q3W).","label":"T-DXd 5.4 mg/kg Q3W","type":"EXPERIMENTAL"},{"description":"Participants will be randomized to receive intravenous T-DXd administered at a dose of 6.4 mg/kg every 3 weeks (Q3W).","label":"T-DXd 6.4 mg/kg Q3W","type":"EXPERIMENTAL"}],"collaborators":["AstraZeneca"],"completion_date":{"date":"2024-12-04","type":"ACTUAL"},"conditions":["Advanced Colorectal Cancer"],"enrollment":{"count":122,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"DS-8201a 5.4 mg/kg Q3W","type":"DRUG"},{"name":"DS-8201a 6.4 mg/kg Q3W","type":"DRUG"}],"last_update":"2026-01-14","lead_sponsor":"Daiichi Sankyo","official_title":"A Phase 2, Multicenter, Randomized, Study of Trastuzumab Deruxtecan in Participants With HER2-overexpressing Locally Advanced, Unresectable or Metastatic Colorectal Cancer (DESTINY-CRC02)","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2022-11-01","type":"ACTUAL"},"primary_outcomes":[{"measure":"Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review Following IV Administration of T-DXd in Participants With Human Epidermal Growth Factor Receptor 2-overexpressing Metastatic Colorectal Cancer","timeFrame":"6 months post-dose administration to data cut off, up to 20 months"}],"references":[{"citation":"Raghav K. Trastuzumab deruxtecan in HER2-positive advanced colorectal cancer: a plain language summary of the DESTINY-CRC02 study. Future Oncol. 2026 Jan;22(2):123-135. doi: 10.1080/14796694.2025.2606418. Epub 2026 Jan 5.","pmid":"41487064","type":"DERIVED"},{"citation":"Raghav K, Siena S, Takashima A, Kato T, Van den Eynde M, Pietrantonio F, Komatsu Y, Kawakami H, Peeters M, Andre T, Lonardi S, Yamaguchi K, Tie J, Castro CG, Hsu HC, Strickler JH, Kim TY, Cha Y, Barrios D, Yan Q, Kamio T, Kobayashi K, Boran A, Koga M, Allard JD, Yoshino T. Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial. Lancet Oncol. 2024 Sep;25(9):1147-1162. doi: 10.1016/S1470-2045(24)00380-2. Epub 2024 Aug 5.","pmid":"39116902","type":"DERIVED"}],"start_date":{"date":"2021-03-05","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer","url":"https://clinicaltrials.gov/study/NCT04744831"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/destiny-crc02-nct04744831"}